Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
73.51
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council
July 15, 2021
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
July 12, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
June 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
June 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Regenerative Medicine Market Size to Reach Revenues of over USD 27 Billion by 2026 – Arizton
June 24, 2021
The global regenerative medicine market size is estimated to reach USD 27.08 billion by 2026, growing at a CAGR of 30% during the forecast period.
Via
EIN Presswire
Topics
Death
Exposures
COVID-19
Death
Product Safety
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
June 24, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Coronavirus Vaccine Investment Market to See Massive Growth by 2026 : Serum Institute of India, BioNTech SE Pfizer, Gilead Sciences
June 23, 2021
Coronavirus Vaccine Investment Comprehensive Study by Type (Government, Private Firms), Application (Hospitals, Research Laboratories, Clinics, Others) Players and Region - Global Market Outlook to...
Via
SBWire
Exposures
COVID-19
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
June 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Adonis Timone Aims to Create Change With Advocates for Youth
June 22, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
June 17, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
COVID-19
Product Safety
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a...
Via
Newsfile
Exposures
COVID-19
Product Safety
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 15, 2021
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
It's Time to Pass the Equality Act
June 15, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
June 12, 2021
From
Kite, a Gilead Company
Via
Business Wire
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
June 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Pharmaceutical Drugs Market Projected to Show Strong Growth : Pfizer, Bayer, Sanofi
June 14, 2021
Keep yourself up-to-date with latest market trends and maintain a competitive edge by sizing up with available business opportunity in Pharmaceutical Drugs Market various segments and emerging...
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
BIO Takes on Health Equity in Clinical Trials
June 10, 2021
First-ever BIO Clinical Trial Diversity Summit will engage stakeholders to build a sustainable and equitable clinical development ecosystem
Via
EIN Presswire
Reducing Our Footprint: It's Time to Get More Ambitious
June 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Climate Change
Emissions
Supply Chain
Exposures
Climate
Supply Chain
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
June 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
ICAN Obtains And Releases Nearly 3,000 Fauci Emails From The Beginning Of The Pandemic; Twitter Account suspended
June 04, 2021
FOIA ruling releases almost 3,000 emails from Anthony Fauci to the public.
Via
EIN Presswire
Topics
Death
Lawsuit
Exposures
COVID-19
Death
Financial
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
June 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
June 03, 2021
Kelowna, British Columbia - TheNewswire - June 3, 2021 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms,...
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lance Toma Creates Safe Spaces for San Francisco's LGBTQ+ AAPI Community
June 03, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Police Brutality
Exposures
Activism
COVID-19
PVP in Pharmaceutical Applications Market May Set New Growth Story : Pfizer, Divnova, GreenCo, Harke, Bonsun
June 02, 2021
Stay up-to-date with PVP in Pharmaceutical Applications Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
Gilead Sciences: Committed to Addressing Barriers That Prohibit Care for Asian American and Native Hawaiian and Pacific Islander Populations
June 02, 2021
SOURCE: Gilead Sciences
Via
3BL Media
2020 R&D Spending and Intensity Benchmarks
June 01, 2021
VIRGINIA BEACH, Va. - June 1, 2021 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, now in its 45th annual edition, the pharmaceutical industry...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
A Comprehensive Study Exploring Covid-19 Therapeutic Market : Key Players AstraZeneca, Novartis, Ascletis Pharma, Pharmstandard
May 26, 2021
The Latest survey report on Global Covid-19 Therapeutic Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Covid-19 Therapeutic...
Via
SBWire
Exposures
COVID-19
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.